| Literature DB >> 34980691 |
Yuzuru Toki1, Ryo Yamauchi2, Eizo Kayashima3, Kyoichi Adachi4, Kiyohiko Kishi5, Hiroshi Suetsugu6, Tsuneya Wada7, Hiroyoshi Endo8, Hajime Yamada9, Satoshi Osaga10, Takeshi Kamiya10, Koji Nakada11, Katsuhiko Iwakiri12, Ken Haruma13, Takashi Joh14.
Abstract
BACKGROUND/AIMS: Although risk factors of reflux esophagitis (RE) have been investigated in numerous cross-sectional studies, little is known about predictive factors associated with future onset of RE. We investigated time courses of clinical parameters before RE onset by a longitudinal case-control study using health checkup records.Entities:
Keywords: Epidemiology; Esophagitis; Longitudinal studies; Risk factors
Year: 2022 PMID: 34980691 PMCID: PMC8748855 DOI: 10.5056/jnm20237
Source DB: PubMed Journal: J Neurogastroenterol Motil ISSN: 2093-0879 Impact factor: 4.924
Figure 1Subject flow in this study. HC, health checkup; UGE, upper gastrointestinal endoscopy; RE, reflux esophagitis.
Subject Characteristics of the Case and Control Groups at Baseline (Continuous Parameters)
| Characteristics | Case group | Control group | ||||
|---|---|---|---|---|---|---|
| N | Mean ± SD | N | Mean ± SD | |||
| Age (yr) | 2066 | 53.9 ± 9.3 | 4132 | 54.0 ± 9.4 | 0.963 | |
| BMI (kg/m2) | 2063 | 23.5 ± 3.3 | 4126 | 22.9 ± 3.0 | < 0.001 | |
| AC (cm) | 2026 | 84.2 ± 9.1 | 4050 | 82.5 ± 8.6 | < 0.001 | |
| FBS (mg/dL) | 2052 | 102.7 ± 18.1 | 4103 | 101.4 ± 16.9 | 0.006 | |
| HbA1c (%) | 1648 | 5.7 ± 0.6 | 3276 | 5.7 ± 0.5 | 0.321 | |
| SBP (mmHg) | 2026 | 112.4 ± 22.3 | 4052 | 110.9 ± 22.0 | 0.011 | |
| DBP (mmHg) | 2026 | 84.3 ± 22.0 | 4052 | 83.1 ± 21.9 | 0.052 | |
| TG (mg/dL) | 2022 | 126.7 ± 90.2 | 4039 | 115.5 ± 72.8 | < 0.001 | |
| HDL-C (mg/dL) | 2025 | 60.4 ± 15.9 | 4052 | 61.5 ± 15.8 | 0.007 | |
| LDL-C (mg/dL) | 1453 | 122.5 ± 30.2 | 2909 | 122.9 ± 29.5 | 0.669 | |
| TC (mg/dL) | 1764 | 206.5 ± 32.6 | 3540 | 206.4 ± 32.9 | 0.889 | |
| UA (mg/dL) | 1779 | 5.69 ± 1.32 | 3555 | 5.57 ± 1.3 | 0.002 | |
| AST (IU/L) | 2025 | 24.1 ± 11.0 | 4052 | 23.0 ± 8.7 | < 0.001 | |
| ALT (IU/L) | 2025 | 26.2 ± 18.2 | 4052 | 23.5 ± 14.7 | < 0.001 | |
| γ-GTP (IU/L) | 2025 | 46.0 ± 49.4 | 4052 | 40.2 ± 44.1 | < 0.001 | |
aP-values were calculated using Student’s t test.
N, total number of subjects in the group (except subjects whose characteristics were unknown); BMI, body mass index; AC, abdominal circumference; FBS, fasting blood sugar; HbA1c, hemoglobin A1c; SBP, systolic blood pressure; DBP, diastolic blood pressure; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol; UA, uric acid; AST, aspartate aminotransferase; ALT, alanine aminotransferase; γ-GTP, γ-glutamyl transpeptidase.
Subject Characteristics of the Case and Control Groups at Baseline (Categorical Parameters)
| Characteristics | Case group | Control group | ||||
|---|---|---|---|---|---|---|
| N | n (%) | N | n (%) | |||
| Male | 2066 | 1558 (75.4) | 4132 | 3116 (75.4) | 1.000 | |
| Current drinking | 1925 | 1379 (71.6) | 3838 | 2680 (69.8) | 0.156 | |
| Amount of alcohol | 1392 | 2740 | < 0.001 | |||
| < 20 g/day | 652 (46.8) | 1418 (51.8) | ||||
| 20-40 g/day | 442 (31.8) | 872 (31.8) | ||||
| 40-60 g/day | 240 (17.2) | 344 (12.6) | ||||
| ≥ 60 g/day | 58 (4.2) | 106 (3.9) | ||||
| Current smoking | 1923 | 471 (24.5) | 3838 | 821 (21.4) | 0.008 | |
| Symptoms | ||||||
| Acid reflux symptoms | 2057 | 239 (11.6) | 4117 | 192 (4.7) | < 0.001 | |
| Gastric pain | 1627 | 90 (5.5) | 3259 | 166 (5.1) | 0.517 | |
| Heavy stomach | 1358 | 136 (10.0) | 2715 | 234 (8.6) | 0.144 | |
| Feeling of fullness | 1244 | 106 (8.5) | 2487 | 167 (6.7) | 0.046 | |
| Belching | 1137 | 75 (6.6) | 2273 | 116 (5.1) | 0.074 | |
| Abdominal pain | 488 | 24 (4.9) | 976 | 46 (4.7) | 0.863 | |
| Endoscopic findings | ||||||
| Hiatal hernia | 1960 | 458 (23.4) | 3916 | 492 (12.6) | < 0.001 | |
| Atrophic gastritis | 1960 | 693 (35.4) | 3917 | 1637 (41.8) | < 0.001 | |
| Barrett’s esophagus | 1960 | 53 (2.7) | 3916 | 127 (3.2) | 0.258 | |
| Comorbidities | ||||||
| Diabetes | 2022 | 174 (8.6) | 4040 | 294 (7.3) | 0.068 | |
| Hypertension | 2022 | 417 (20.6) | 4040 | 704 (17.4) | 0.003 | |
| Hyperlipidemia | 2022 | 351 (17.4) | 4040 | 620 (15.4) | 0.044 | |
| 33 | 13 (39.4) | 87 | 46 (52.9) | 0.187 | ||
aP-values were calculated using chi-square test.
N, total number of subjects in the group (except subjects whose characteristics were unknown); H. pylori, Helicobactor pylori.
Multivariate Logistic Regression Analysis for Baseline Characteristics
| Characteristics | Adjusted OR [95% CI] | |
|---|---|---|
| BMI (per 1 kg/m2 increase) | 1.05 [1.03, 1.07] | < 0.001 |
| ALT (per 10 IU/L increase) | 1.05 [1.02, 1.09] | 0.004 |
| Current smoking | 1.15 [1.01, 1.32] | 0.035 |
| Acid reflux symptoms | 2.72 [2.22, 3.33] | < 0.001 |
| Hiatal hernia | 2.32 [2.01, 2.69] | < 0.001 |
| Atrophic gastritis | 0.66 [0.58, 0.74] | < 0.001 |
aUnit ORs are presented for continuous variables.
BMI, body mass index; ALT, alanine aminotransferase.
A higher OR indicates a higher risk of having reflux esophagitis given each characteristic.
Figure 2Time courses of the factors that were significantly different between the case and control groups in the longitudinal comparison. For continuous variables, points and error bars denote least square means at each year and its standard errors, respectively. For categorical variables, boxes denote percentages at each year. HDL, high-density lipoprotein; AST, aspartate aminotransferase; ALT, alanine aminotransferase; γ-GTP, γ-glutamyl transpeptidase. *P < 0.05; **P < 0.01; ***P < 0.001 in the cross-sectional comparisons between the groups. #P-value in the longitudinal comparison between the groups.